J-Pharma Co.,Ltd.
| Code | Sector | Market |
|---|---|---|
| 520A | Pharmaceuticals | Growth |
| Date of listing approval | 2026/02/19 |
|---|---|
| Expected Date | 2026/03/25 |
| Lead Underwriter | SBI SECURITIES Co.,Ltd. |
| Description |
| Listed Shares(total) | 3,240,200 |
|---|---|
| Trading Unit | 100 |
| New Shares | 3,240,000 |
| Existing Shares | 200 |
| Shares Outstanding | PreIPO 14,589,610.00 |
| PostIPO 17,829,610.00 | |
| Paid Up Capital | PreIPO Y682,700,000 |
| PostIPO | |
| Expected Pricing Date | 2026/03/05 |
| Book Building Start | 2026/03/06 |
| Book Building End | 2026/03/12 |
| Fix Date | 2026/03/13 |
| Offering Starts | 2026/03/16 |
| Offering Ends | 2026/03/19 |
| Expect Pricing | - |
| Notional PER (based on previous period) |
- |
| Offering Price | |
| Offering Price PER (based on previous period) |
- |
| Offering Price PBR (based on previous period) |
|
| Use of Funds Raised |
Financial Data
Units:Y1,000
| Fiscal Year End:2023/03 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | - |
| Current Profit | - | -1,086,760 |
| Net Profit | - | -1,098,260 |
| Net Assets | - | 1,407,818 |
| Fiscal Year End:2024/03 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | - |
| Current Profit | - | -1,640,255 |
| Net Profit | - | -1,652,337 |
| Net Assets | - | 950,122 |
| Fiscal Year End:2025/03 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | - |
| Current Profit | - | -1,527,089 |
| Net Profit | - | -1,499,008 |
| Net Assets | - | 2,377,869 |
| Recent Quarter 2025/12 |
||
|---|---|---|
| Consolidated | Non-consolidated | |
| Revenue | - | - |
| Current Profit | - | -2,047,444 |
| Net Profit | - | -1,876,851 |
| Net Assets | - | 2,344,635 |
Per Share Units:Y1
| Fiscal Year End:2023/03 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - |
| Equity | -190.55 | -789.60 |
| Fiscal Year End:2024/03 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - |
| Equity | -263.57 | -926.67 |
| Fiscal Year End:2025/03 | ||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | 0.00 | |
| Net Earning | - | - |
| Equity | -184.05 | -734.62 |
| Fiscal Year End:Recent Quarter 2025/12 |
||
|---|---|---|
| Consolidated | Non-consolidated | |
| Dividend | ||
| Net Earning | - | -157.57 |
| Equity | - | - |
Comment
| ąŁOver allotment (486,000) |
Consolidated Subsidiaries
| Name | Address |
|---|
Underwriters
| Allocation | Underwriter | Tel |
|---|---|---|
| 0% | Nomura | 03-3211-1811 |
| 0% | SBI SECURITIES Co.,Ltd. | 03-5562-7210 |
| 0% | Daiwa Securities Co. Ltd | 03-5555-2111 |
| 0% | Tokai Tokyo Securities Co., Ltd | 03-3566-8811 |
| 0% | TOYO SECURITIES CO.,LTD | 03-5117-1040 |
| 0% | Matsui Securities Co., Ltd | 03-5216-0606 |
| 0% | Monex, Inc | 03-4323-3800 |
| 0% | Rakuten Securities Holdings, Inc. | 03-6406-2681 |
Data
| Date of incorporation | 2005/12/26 |
|---|---|
| Company address | Tokyo 105-0013 |
| Telephone | 03-6432-4270 |
| President | |
| Homepage | https://www.j-pharma.com/ |
| Auditor | GINGA Audit |
| Major Shareholders | |
|---|---|
| Shareholder Name | Ratio |
| 86.62% | |
| 12.82% | |
| 12.30% | |
| 7.77% | |
| 5.55% | |
| 3.96% | |
| 3.80% | |
| 3.34% | |
| 3.07% | |
| 2.93% | |
| 2.79% | |
| Number of Employees | 16 as of 2026/01/31 |
|---|---|
| Birth Date of Representative | 1959/02/03 |